

AUROBAC THERAPEUTICS UK Ltd

Tax strategy 2025

In accordance with UK legislation, Schedule 19 of the UK Finance Act 2016, the company is publishing its tax strategy for the Year Ending 31st December 2025, which will be updated annually. This is approved by the Board of Directors.

AUROBAC THERAPEUTICS SAS ensures that all its affiliates act in line with applicable local laws.

1. Tax Risk Management & Governance

We aim for our tax affairs to be compliant with UK tax legislation. The Board has delegated responsibility for the Tax Strategy and Compliance to our Finance Director, who updates the Board on key tax issues on an annual basis.

The UK entity actively reviews and updates its tax risk management and governance processes, including how tax risk is identified, assessed and mitigated.

Our Corporate Tax Computations and Returns are prepared by a professional firm who also assists us with tax technical updates and flagging new legislation to help reduce the risk of non-compliance. We also work with appropriately qualified and experienced partners to prepare and submit relevant returns, such as VAT (if relevant) and social returns.

Our tax accounting is reviewed annually as part of the annual independent audit.

2. Attitude to tax planning

We will consider a range of tax outcomes based on the underlying commercial intention of any business activity or transaction that supports our business activities and the group's code of conduct, rather than looking for ways to aggressively avoid the payment of tax. We seek to balance the shareholders' interest of managing business expenses, which include taxation, with ensuring that any arrangements comply with current UK tax legislation. Intercompany transactions are conducted on arm's length principles following international standards and UK legislation.

Level of tax risk

Due to the size of the business, there is a minor degree of tax risk. We recognise that eliminating tax risk entirely is impossible, but we aim to manage our tax risk as far as practically possible.

In areas of uncertainty where tax risk arises from the complexity of tax legislation and differences in interpretation, we will seek appropriate external advice before engaging with HMRC.

Our approach is to aim to be compliant and understand our responsibilities with regards to tax and we will claim legitimate tax incentives, exemptions and reliefs offered by the UK Government to all taxpayers.

3. Approach towards HMRC

AUROBAC THERAPEUTICS UK Ltd is committed to the same principles of openness and transparency in its approach to dealing with HMRC and Revenue as its parent companies, and is committed to:

- Make fair, accurate and timely disclosure in correspondence and returns, and respond to queries and information requests in a timely fashion.
- If tax enquiries or audits are opened, we work collaboratively to resolve and to achieve early agreement and certainty.
- Interpret the relevant laws in a reasonable way, and ensure transactions are structured consistently.
- Ensure all interactions with tax authorities are conducted in an open, collaborative, and professional manner.
- Ensure the correct amount of tax is paid as and when it falls due.